Machado-Joseph disease
| Machado-Joseph disease | |
| ICD-10 | G11.1 |
|---|---|
| ICD-9 | 334.2 |
| OMIM | 109150 |
| DiseasesDB | 31961 |
| MeSH | D017827 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Machado-Joseph disease is a type of spinocerebellar ataxia caused by a mutation in the ATXN3 gene.
It causes ophthalmoplegia and mixed sensory and cerebellar ataxia
It is also known as Spinocerebellar ataxia type 3.
It was first identified in 1972.[1]
Machado-Joseph Disease is a rare, inherited disease that causes lack of muscle control. Chromosome 14 is where the gene that is responsible for MJD is located.
Based on DNA studies, MJD is the most widespread, autosomal dominant inherited form of ataxia in the world.
Symptoms
Symptoms of MJD are spasticity, difficulty with speech and swallowing, weakness in arms and legs, clumsiness, frequent urination and involuntary eye movements. Symptoms can being in early adolescence and they get worse over time. There is no cure for Machado-Joseph Disease, however, there are treatments available for some symptoms. For example, spasticity can be reduced with Antispasmodic drugs, such as baclofen. Eventually, MJD leads to paralysis however, intellectual functions usually remain the same.
Prognosis
Life expectancy ranges with people who have the disease. A normal life expectancy is expected in patients with a mild form of MJD. Those with severe forms of MJD are expected to live only to their mid-thirties. The cause of death of those who die early is often aspiration pneumonia.
Pathophysiology
MJD has lengthy irregular repetition of the DNA genetic code located within a gene on chromosome 14q. The code "CAG" is repeated and produces a mutated protein called ataxin-3. In affected cells, this protein piles up and assembles intranuclear inclusion bodies.
These insoluble spheres are located in the nucleus of the cell. These spheres conflict with the normal activity of the nucleus and induce the cell to degenerate and die.
Classification
The types of MJD are characterized by the onset and age and range of symptoms.
- Type I is distinguished by arrival between the ages of 10 and 30 years of age. It usually has fast development and severe rigidity and dystonia.
- Type II typically begins between 20 and 50 years of age. It has an intermediate progression and causes symptoms that include spasticity, exaggerated reflex responses and spastic gait.
- Type III MJD has a slow progression. Symptoms include muscle twitching, tingling, cramps, unpleasant sensations such as numbness, pain in the feet, hands and limbs and muscle atrophy. Patients typically have an onset between the ages of 40 and 70. Nearly all patients experience a decline in their vision such as blurred vision, double vision, inability to control eye movements, and loss of capability to distinguish color. Some patients also experience Parkinson’s-like symptoms.
Diagnosis
MJD can be diagnosed by recognizing the symptoms of the disease and by taking a family history. Physicians ask patients questions about the kind of symptoms relatives with the disease had, the progression and harshness of symptoms, and the ages of onset in family members. The best diagnosis of MJD can be made only with a genetic test.